Loading...
XCNQ
ENBI
Market cap893kUSD
, Last price  
CAD
Name

Entheon Biomedical Corp

Chart & Performance

D1W1MN
XCNQ:ENBI chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
78.57%
Rev. gr., 5y
%
Revenues
0k
-100.00%
00000021,670189,677250,3230
Net income
-318k
L+6.00%
-8,862-1,859-144,981-157,534-667,267-4,378,032-8,669,912-7,031,923-300,001-318,000
CFO
-356k
L-1.19%
-8,784-2,033-67,492-221,312-102,317-2,837,522-5,615,218-1,954,608-359,929-355,639

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
IPO date
May 03, 2018
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2024‑112023‑112022‑112021‑112020‑112020‑032019‑112019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT